<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190005</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-10603117-E</org_study_id>
    <nct_id>NCT03190005</nct_id>
  </id_info>
  <brief_title>Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)</brief_title>
  <official_title>Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment (A Possible Mechanism of HOTPR:High On- Treatment Platelet Reactivity)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed the following experiment to observe the pattern of administration
      in vitro, which can be completely excluded liver enzyme cytochrome P450 metabolism under the
      influence and observe the relevant P2Y12 receptor downstream signal changes, hope in the
      above experiments, that the human body directly for the difference between the existence of
      drug reactions exist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet reactivity has been accepted as an indicator of the reaction of the P2Y12 inhibitor
      during treatment, currently, the existing evidence to support the post-treatment platelet
      activity can be used to distinguish the potential risk among patients who received
      percutaneous transluminal coronary angioplasty after ischemic / thrombotic events. The risks
      of stent thrombosis, of which, by analysis of the PRU (P2Y12 reaction units) value level of
      VerifyNow System has been considered an international standard tools. PRU value by VerifyNow
      system can easily and quickly showed platelet reactivity relative to short or long term risk
      stratification under dual antiplatelet agents(aspirin and clopidogrel) after stents
      implantation. High PRU response units (drug poor responders) in accordance with the 2013
      publication of the European Society of Cardiology guidelines defined of platelet function, is
      PRU not less than 208(≥208).

      The investigators ran a previous related plan within 2014 under the medical study project
      budget of the Taipei City hospital, which named &quot;platelet reactivity as a post-percutaneous
      coronary stent implantation antiplatelet adjust the reference&quot;, it has been figured that
      responsibility under the P2Y12 receptor inhibitors were significantly different between the
      taiwanese and Caucasians (taiwanese revealed clopidogrel lower responsive, but stronger
      reaction to ticagrelor), although &quot;low&quot; response to clopidogrel between taiwanese (In fact,
      according to our experiments, 30 days after medication, the rate of HOTPR-High On- Treatment
      Platelet Reactivity; namely PRU≥208, the taiwanese and Caucasians are very close to each),
      but it has relative lower subacute stent thrombosis rate than the Caucasian at 30 days(This
      reaction is also known as the &quot;Asian paradox&quot; ), according to literature known abroad because
      of the high prevalence of CYP2C19 point gene deletion rate among the Asians (compare with
      Caucasians: ~ 65% vs ~ 30%); there also suggested other possible explanations: Caucasian
      factor V Leiden (G1691A) and prothrombin (G20210A) a higher proportion of mutations, on
      hemostatic factors (fibrinogen, d-dimer, and factor VIII) and plasma endothelial activation
      markers (such as von Willebrand factor, intercellular adhesion molecule 1, and E-selectin)
      existed differences between the races; in addition, a number of different indicators of
      inflammation, such as CRP. Asians show lower level CRP than the Caucasians. However, did the
      investigators found the true answer? So, the investigators designed the following experiment,
      through the mode of drug administration in vitro, can completely exclude the influence of the
      liver metabolic enzyme cytochrome P450, and observe the relevant downstream signals of P2Y12
      receptors. The investigators believed through the current study, the internal differences in
      drug responsibility can be clarified.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication</measure>
    <time_frame>24 hours</time_frame>
    <description>PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>placebo control without medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <description>hyper-reactive responser after clopidogrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <description>hypo-reactive responser after clopidogrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <description>normo-reactive responser after clopidogrel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 5</arm_group_label>
    <description>reaction after OPC-13013</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 6</arm_group_label>
    <description>reaction after AR-C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 7</arm_group_label>
    <description>reaction after simastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>no medication, healthy subjects.</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      downstream molecular signals of P2Y12 receptor in the platelet(Platelet Rich Plasma).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        stable angina who received routine dual antiplatelet agents therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DAPT(Dual antiplatelet therapy) after regular stent implantation.

        Exclusion Criteria:

          -  allergy to DAPT(Dual antiplatelet therapy). major bleeding intolerance to DAPT(Dual
             antiplatelet therapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei city hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>November 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2019</results_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PRU</keyword>
  <keyword>P2Y12 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03190005/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03190005/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03190005/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>placebo control without medication.
Placebos: no medication, healthy subjects.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>hyper-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>hypo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>normo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="P5">
          <title>Group 5</title>
          <description>reaction after OPC-13013</description>
        </group>
        <group group_id="P6">
          <title>Group 6</title>
          <description>reaction after AR-C</description>
        </group>
        <group group_id="P7">
          <title>Group 7</title>
          <description>reaction after simastatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>patient receive different anti-platelet drug(in vivo or in vitro)</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>placebo control without medication.
Placebos: no medication, healthy subjects.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>hyper-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>hypo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>normo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="B5">
          <title>Group 5</title>
          <description>reaction after OPC-13013</description>
        </group>
        <group group_id="B6">
          <title>Group 6</title>
          <description>reaction after AR-C</description>
        </group>
        <group group_id="B7">
          <title>Group 7</title>
          <description>reaction after simastatin</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="35"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>blood samples</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.52" spread="11.12"/>
                    <measurement group_id="B2" value="64.92" spread="13.24"/>
                    <measurement group_id="B3" value="66.89" spread="10.72"/>
                    <measurement group_id="B4" value="63.35" spread="13.62"/>
                    <measurement group_id="B5" value="65.09" spread="11.13"/>
                    <measurement group_id="B6" value="61.23" spread="10.34"/>
                    <measurement group_id="B7" value="68.32" spread="15.12"/>
                    <measurement group_id="B8" value="67.36" spread="13.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication</title>
        <description>PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication</description>
        <time_frame>24 hours</time_frame>
        <population>PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>placebo control without medication.
Placebos: no medication, healthy subjects.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>hyper-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>hypo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>normo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
          <group group_id="O5">
            <title>Group 5</title>
            <description>reaction after OPC-13013
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
          <group group_id="O6">
            <title>Group 6</title>
            <description>reaction after AR-C
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
          <group group_id="O7">
            <title>Group 7</title>
            <description>reaction after simastatin
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
          </group>
        </group_list>
        <measure>
          <title>PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication</title>
          <description>PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication</description>
          <population>PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication</population>
          <units>PRU(Platelet Rreactivity Unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>blood sample</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>blood sample</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" spread="3"/>
                    <measurement group_id="O2" value="289" spread="4"/>
                    <measurement group_id="O3" value="79" spread="1"/>
                    <measurement group_id="O4" value="132" spread="6"/>
                    <measurement group_id="O5" value="81" spread="3"/>
                    <measurement group_id="O6" value="62" spread="2"/>
                    <measurement group_id="O7" value="114" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>major/minor drug reaction</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>placebo control without medication.
Placebos: no medication, healthy subjects.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>hyper-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>hypo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>normo-reactive responser after clopidogrel.
clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)</description>
        </group>
        <group group_id="E5">
          <title>Group 5</title>
          <description>reaction after OPC-13013</description>
        </group>
        <group group_id="E6">
          <title>Group 6</title>
          <description>reaction after AR-C</description>
        </group>
        <group group_id="E7">
          <title>Group 7</title>
          <description>reaction after simastatin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>chen yueh-chung</name_or_title>
      <organization>taipei city hospital</organization>
      <phone>88627093600 ext 3741</phone>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

